Investigating how a specific receptor affects immune cells in brain tumors.
Official title: Understanding the role of triggering receptor expressed on myeloid cells 2 (TREM2) on microglia and macrophages in gliomas
Funded at University of Texas Hlth Sci Ctr Houston · NIH-11071627 · Data updated 2026-11-12
This study is looking at how a specific receptor called TREM2 affects immune cells in the brain to better understand gliomas, a type of aggressive brain cancer, and hopes to find new ways to improve treatments for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | January 3, 2025 |
| Project end | September 3, 2027 |
| Funding year | 2025 |
| Award (this year) | $37,034 |
| NIH project number | 1F31NS141605-01 |
| Project ID | NIH-11071627 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with gliomas who are seeking new treatment options.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with gliomas may not benefit from this research.
What this research studies
This research focuses on gliomas, a type of aggressive brain cancer, and aims to understand the role of a receptor called TREM2 on immune cells known as microglia and macrophages. By studying how TREM2 influences these cells, the research seeks to uncover mechanisms that could either promote or inhibit tumor growth. The approach involves using specialized mice models to analyze the effects of TREM2 expression on immune responses in the brain. This could lead to new insights into how to improve treatments for glioma patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for glioma patients, potentially improving their treatment outcomes.
How similar studies have gone: Previous research has shown mixed results regarding TREM2's role in gliomas, indicating that this area is still being explored and could lead to novel findings.
Where this research is happening
-
University of Texas Hlth Sci Ctr Houston
Houston, United States Active
Researchers
- Principal investigator: Peshoff, Mekenzie — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Peshoff, Mekenzie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.